Annexon Biosciences Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 48
Employees
  • Stock Symbol
  • ANNX
Stock Symbol
  • Share Price
  • $17.81
  • (As of Tuesday Closing)

Annexon Biosciences General Information

Description

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 180 Kimball Way
  • 2nd Floor, Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Annexon Biosciences Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Annexon Biosciences Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.81 $18.48 $15.33 - $38.01 $681M 38.2M 173K -$4.15

Annexon Biosciences Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 584,399 584,399
Revenue 0 0 0 0
EBITDA (62,745) (62,745) (36,686) (17,815)
Net Income (63,412) (63,412) (37,183) (18,304)
Total Assets 355,946 355,946 49,898 48,149
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Annexon Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Annexon Biosciences‘s full profile, request access.

Request a free trial

Annexon Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Annexon Biosciences‘s full profile, request access.

Request a free trial

Annexon Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with cla
Drug Discovery
South San Francisco, CA
48 As of 2020
00000
0000 0000-00-00
00000000 00000

000000 0

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qu
0000 000000000
Burlingame, CA
00 As of 0000
00000
000000 - 000 00000

0000000

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000000000000
Lexington, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Annexon Biosciences Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Corvus Pharmaceuticals Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Lexington, MA 00 00000 000000000 00000
000000000 00000000 Formerly VC-backed Zurich, Switzerland 000 00000 00000000 00000
000000000 00000000 Formerly VC-backed San Diego, CA 00 00000 000000 - 000 00000
0000 0000 00000000 Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
You’re viewing 5 of 60 competitors. Get the full list »

Annexon Biosciences Executive Team (10)

Name Title Board Seat Contact Info
Douglas Love JD Chief Executive Officer & Board Member
Jennifer Lew Chief Financial Officer & Executive Vice President
Ted Yednock Ph.D Chief Scientific Officer & Executive Vice President
Michael Overdorf Executive Vice President & Executive
Sanjay Keswani Chief Medical Officer & Executive Vice President
You’re viewing 5 of 10 executive team members. Get the full list »

Annexon Biosciences Board Members (12)

Name Representing Role Since
Douglas Love JD Annexon Biosciences Chief Executive Officer & Board Member 000 0000
Frank Torti MD New Enterprise Associates Board Member 000 0000
Giovanni Ferrara Novartis Venture Fund Board Member 000 0000
Jung Choi Self Board Member 000 0000
Muneer Satter JD Satter Foundation Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Annexon Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Annexon Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Annexon Biosciences‘s full profile, request access.

Request a free trial